Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sanofi

Peer review: Can this critical step in the publication of science research be kinder?

Democracy has been called the least worst system of government. Peer review is the least worst system for assessing the merit of scientific work.

The Conversation

The hard road for the Novavax vaccine

Novavax now in financial trouble after missing peak vaccinations

Salon

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugmakers urged to give poorer nations access to more antibiotics

Antifungals also needed, says study, as drug resistance has increased faster than expected, particularly in sub-Saharan Africa

The Guardian - UK

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Benzinga

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Tribune News Service

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects

A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate.

Benzinga

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was attributed by management to longer sales cycles in the insurer and employer space in addition to competitive concerns.

Benzinga

Why Kymera Therapeutics Shares Are Falling Today

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ:KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). In…

Benzinga

Dupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance

Sanofi SA (NASDAQ:SNY) posted a net profit of €2 billion for Q1 FY22, up from €1.57 billion a year ago. Sales reached €9.67 billion, up from €8.59 billion in Q1 FY21. Eczema drug, Dupixent, and consumer healthcare drove the growth. Dupixent alone grew by 45.7% to €1.6 billion, driving Sanofi's specialty care…

Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

Benzinga

Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran

Terran Biosciences is slowly but surely finding its place in the psychedelics industry.

Benzinga

How To Attend Sanofi Q1 2022 Earnings Conference Call

Sanofi (NASDAQ:SNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

Results from the Phase 1/2 dose-finding study evaluating Sanofi SA's (NASDAQ:SNY) rilzabrutinib in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrate that rilzabrutinib treatment led to a rapid and durable increase in platelet count and supports an acceptable safety profile. Sanofi is investigating…

Tribune News Service

Why Black and Hispanic seniors are left with a less powerful flu vaccine

At Whitman-Walker Health, Dr. David Fessler and his staff administer high-dose influenza vaccine to all HIV-positive and senior patients. Although the vaccine is roughly three times as expensive as standard flu vaccine, it seems to do a better job at protecting those with weakened immune systems — a major focus…

Benzinga

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May

Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

Benzinga

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi

Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against

Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

20 Stocks Moving in Tuesday's Pre-Market Session

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY).

Benzinga

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

The FDA has cleared Adagene Inc's (NASDAQ:ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab). The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumors. The ADG126-P001 trial is expected to dose the first patients soon. The trial is…

Benzinga

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Why Sanofi Shares Are Trading Lower Today

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer,

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.